Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Atomera Incorporated (ATOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Atomera Incorporated — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.73 (market cap $4.49B), while Atomera Incorporated trades at $6.63 (market cap $284.76M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 15.8× Atomera Incorporated's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Atomera Incorporated nearer its low. Which is the better fit depends on your goals.
| ACAD | ATOM | |
|---|---|---|
Market Cap | $4.49B | $284.76M |
Sector | Health | Technology |
52-Week High | $28.06 | $12.11 |
52-Week Low | $20.06 | $1.99 |
Enterprise Value | $3.69B | $244.97M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ATOM trades at $7.355, down 0.74% with bearish technical signals. The company shows severe financial distress with negative gross margins of -520.83% and net losses of -$20.17 million in 2025. Recent earnings misses and negative cash flow highlight operational challenges despite 100% analyst buy ratings. Technical indicators show bearish momentum with support at $7 and resistance at $8.
The outlook remains highly speculative given extreme financial losses and negative cash flow. Investment opportunity hinges on successful commercialization of GaN semiconductor technology, while risks include continued cash burn and failure to achieve revenue growth. The stock represents a high-risk bet on unproven technology execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →
